Walleye Capital LLC Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Walleye Capital LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 72,009 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,981,000. Walleye Capital LLC owned about 0.34% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. HighTower Advisors LLC purchased a new position in ANI Pharmaceuticals in the third quarter valued at approximately $222,000. Stifel Financial Corp purchased a new position in ANI Pharmaceuticals during the third quarter valued at approximately $418,000. State Street Corp increased its holdings in shares of ANI Pharmaceuticals by 9.1% in the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after purchasing an additional 58,698 shares during the period. Barclays PLC increased its stake in ANI Pharmaceuticals by 1,681.2% in the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after acquiring an additional 135,003 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after purchasing an additional 17,314 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ANIP. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective on the stock. Guggenheim reiterated a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

Insiders Place Their Bets

In other news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,200 shares of company stock valued at $197,792. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $69.20 on Thursday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.18. The firm has a market cap of $1.51 billion, a PE ratio of -125.82 and a beta of 0.49. The firm has a fifty day simple moving average of $62.88 and a two-hundred day simple moving average of $59.29.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.